Macarena Piñero-Saavedra1, Teresa González-Quevedo2, Blanca Saenz de San Pedro3, Cristina Alcaraz4, Pedro Bobadilla-González5, Lourdes Fernández-Vieira6, Belén Hinojosa7, Raúl García-Lozano8. 1. Reference Unit for Angioedema in Andalusia, Allergy Department, Virgen del Rocío University Hospital, Seville, Spain. 2. Reference Unit for Angioedema in Andalusia, Allergy Department, Virgen del Rocío University Hospital, Seville, Spain. Electronic address: mtgonzalezq@gmail.com. 3. Allergy Department, Jaen Hospital Complex, Jaen, Spain. 4. Allergy Department, Virgen Macarena University Hospital, Seville, Spain. 5. Allergy Department, Infanta Cristina University Hospital, Badajoz, Spain. 6. Allergy Department, Clideba Hospital, Badajoz, Spain. 7. Allergy Department, Virgen de la Cinta Specialities Center, Huelva, Spain. 8. Immunology Department, Virgen del Rocío University Hospital, Seville, Spain.
Abstract
BACKGROUND: Information on F12 mutation hereditary angioedema (HAE) is still limited, but Spain is now recognized as having one of the highest concentrations of cases in Western Europe. OBJECTIVE: To describe unique features of HAE in Spanish carriers of the F12 mutation and investigate a potential role for angiotensin-converting enzyme (ACE) and aminopeptidase-P polymorphisms in disease expression. METHODS: This was a prospective observational cohort study of 35 individuals (80% females) from 9 unrelated families carrying the p.Thr309Lys mutation. We analyzed detailed medical records and complement activity (C4, C1q, C1 inhibitor) and screened for mutations in exon 9 of the F12 gene and 2 polymorphisms: XPNPEP2 c-2399A and the ACE insertion/deletion polymorphism. RESULTS: The p.Thr309Lys mutation was found in all individuals. Three of the 9 index patients had a clinically negative family history, and 72% of males and 29% of females were asymptomatic. Sixteen females (44% estrogen dependent, 56% estrogen sensitive) were clearly symptomatic. The most common locations of attacks were the abdomen (63%), face (25%), and peripheral structures (6%). Triggers other than hyperestrogenic states included stress and minor trauma or pressure. Short-term treatment with C1-inhibitor concentrate and icatibant and long-term prophylaxis with tranexamic acid were useful. The combination of the I allele and A allele was detected in 17% of patients. CONCLUSION: The polymorphisms analyzed were not a major determinant of disease expression in our population. We recommend searching for F12 mutations in women with edema attacks without associated wheals and with normal C1-inhibitor levels, particularly when they develop symptoms during hyperestrogenic states or are of Western European or African origin.
BACKGROUND: Information on F12 mutation hereditary angioedema (HAE) is still limited, but Spain is now recognized as having one of the highest concentrations of cases in Western Europe. OBJECTIVE: To describe unique features of HAE in Spanish carriers of the F12 mutation and investigate a potential role for angiotensin-converting enzyme (ACE) and aminopeptidase-P polymorphisms in disease expression. METHODS: This was a prospective observational cohort study of 35 individuals (80% females) from 9 unrelated families carrying the p.Thr309Lys mutation. We analyzed detailed medical records and complement activity (C4, C1q, C1 inhibitor) and screened for mutations in exon 9 of the F12 gene and 2 polymorphisms: XPNPEP2 c-2399A and the ACE insertion/deletion polymorphism. RESULTS: The p.Thr309Lys mutation was found in all individuals. Three of the 9 index patients had a clinically negative family history, and 72% of males and 29% of females were asymptomatic. Sixteen females (44% estrogen dependent, 56% estrogen sensitive) were clearly symptomatic. The most common locations of attacks were the abdomen (63%), face (25%), and peripheral structures (6%). Triggers other than hyperestrogenic states included stress and minor trauma or pressure. Short-term treatment with C1-inhibitor concentrate and icatibant and long-term prophylaxis with tranexamic acid were useful. The combination of the I allele and A allele was detected in 17% of patients. CONCLUSION: The polymorphisms analyzed were not a major determinant of disease expression in our population. We recommend searching for F12 mutations in women with edema attacks without associated wheals and with normal C1-inhibitor levels, particularly when they develop symptoms during hyperestrogenic states or are of Western European or African origin.
Authors: Camila Lopes Veronez; Anne Aabom; Renan Paulo Martin; Rafael Filippelli-Silva; Rozana Fátima Gonçalves; Priscila Nicolicht; Agatha Ribeiro Mendes; Jane Da Silva; Mar Guilarte; Anete Sevciovic Grumach; Eli Mansour; Anette Bygum; João Bosco Pesquero Journal: Front Med (Lausanne) Date: 2019-02-21
Authors: Itahisa Marcelino-Rodriguez; Ariel Callero; Alejandro Mendoza-Alvarez; Eva Perez-Rodriguez; Javier Barrios-Recio; Jose C Garcia-Robaina; Carlos Flores Journal: Front Genet Date: 2019-09-27 Impact factor: 4.599
Authors: Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Bassem M Mohammed; Qiufang Cheng; S Kent Dickeson; Suman Kundu; Ingrid M Verhamme; Andras Gruber; Keith McCrae; David Gailani Journal: Blood Date: 2018-12-27 Impact factor: 25.476